Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study

BACKGROUND: Primary SARS-CoV-2 vaccination has been shown to wane with time and provide lower protection from disease with new viral variants, prompting the WHO to recommend the administration of booster doses. We determined the safety and immunogenicity of homologous or heterologous boosters with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Winsley, Raju, Reshma, Babji, Sudhir, George, Anna, Madhavan, Ramya, Leander Xavier, Julian Vivek, David Chelladurai, Jenita Sharon, Nikitha, Origanti Sharon, Deborah, Arpitha Anbu, Vijayakumar, Shalini, Immanuel, Sushil, John, Jacob, Rupali, Priscilla, Abhilash, Kundavaram P.P., Mohan, Venkata Raghava, Tallapaka, Karthik Bharadwaj, Samuel, Prasanna, Kang, Gagandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870748/
https://www.ncbi.nlm.nih.gov/pubmed/36712811
http://dx.doi.org/10.1016/j.lansea.2023.100141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870748/
https://www.ncbi.nlm.nih.gov/pubmed/36712811
http://dx.doi.org/10.1016/j.lansea.2023.100141

Ejemplares similares